FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

П

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

## OMB APPROVAL

OMB Number:	3235-0287
Expires:	December 31, 2014
Estimated aver	age burden
hours per response	0.5

ction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> WILSON ROBERT N	2. Issuer Name <b>and</b> Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [SNTA]						
(Last) (First) (Middle) C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2013	(Check all applicable) X Director 10% Owner Officer (give title below) (specify below)					
(Street)LEXINGTONMA02421(City)(State)(Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing</li> <li>(Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One</li> <li>Reporting Person</li> </ul>					

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code Disposed of			Securities 5. Amount of Securities sposed of (D) str. 3, 4 and 5)			6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)		
Common Stock	07/01/2013		А		2,000 (1)	Α	<b>\$</b> 0 <sup>(1)</sup>	701,679	D			

Table II - Derivative Securities Acquired, Disposed of, or Benefi           (e.g., puts, calls, warrants, options, convertible security	-	wned	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8)		Number of Derivative		and Expiration Date		n Amount of Underlying		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Director Stock Option (Right to Buy)	\$ <del>5</del>	07/01/2013		A		10,000		(2)	07/01/2023	Common Stock	10,000	\$0	10,000	D	

## **Explanation of Responses:**

1. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as director of the Issuer on such date.

2. The option vests as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as a director of the Issuer on such date.

/s/ Brian Keane, Attorneyin-Fact \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.